Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, WI 53711, USA.
Immunogenetics. 2011 Sep;63(9):587-97. doi: 10.1007/s00251-011-0538-4. Epub 2011 May 31.
The presentation of identical peptides by different major histocompatibility complex class I (MHC-I) molecules, termed promiscuity, is a controversial feature of T cell-mediated immunity to pathogens. The astounding diversity of MHC-I molecules in human populations, presumably to enable binding of equally diverse peptides, implies promiscuity would be a rare phenomenon. However, if it occurs, it would have important implications for immunity. We screened 77 animals for responses to peptides known to bind MHC-I molecules that were not expressed by these animals. Some cases of supposed promiscuity were determined to be the result of either non-identical optimal peptides or were simply not mapped to the correct MHC-I molecule in previous studies. Cases of promiscuity, however, were associated with alterations of immunodominance hierarchies, either in terms of the repertoire of peptides presented by the different MHC-I molecules or in the magnitude of the responses directed against the epitopes themselves. Specifically, we found that the Mamu-B017:01-restricted peptides Vif HW8 and cRW9 were also presented by Mamu-A205:26 and targeted by an animal expressing that allele. We also found that the normally subdominant Mamu-A1001:01 presented peptide Gag QI9 was also presented by Mamu-B056:01. Both A205:26 and B056:01 are molecules typically or exclusively expressed by animals of Chinese origin. These data clearly demonstrate that MHC-I epitope promiscuity, though rare, might have important implications for immunodominance and for the transmission of escape mutations, depending on the relative frequencies of the given alleles in a population.
不同主要组织相容性复合体 I 类 (MHC-I) 分子呈现相同的肽,称为混杂性,这是 T 细胞介导的针对病原体免疫的一个有争议的特征。人群中 MHC-I 分子的惊人多样性,大概是为了能够结合同样多样化的肽,暗示混杂性将是一种罕见的现象。然而,如果它发生了,它将对免疫产生重要影响。我们筛选了 77 种动物对已知结合这些动物不表达的 MHC-I 分子的肽的反应。一些所谓的混杂性病例被确定为要么是非同源最优肽的结果,要么在之前的研究中只是没有映射到正确的 MHC-I 分子。然而,混杂性病例与免疫优势层次的改变有关,要么是不同 MHC-I 分子所呈现的肽谱的改变,要么是针对表位本身的反应幅度的改变。具体来说,我们发现,Mamu-B017:01 限制的肽 Vif HW8 和 cRW9 也被 Mamu-A205:26 呈现,并被表达该等位基因的动物靶向。我们还发现,通常处于次要地位的 Mamu-A1001:01 呈现的肽 Gag QI9 也被 Mamu-B056:01 呈现。A205:26 和 B056:01 都是通常或专门由中国起源的动物表达的分子。这些数据清楚地表明,尽管 MHC-I 表位混杂性罕见,但根据特定等位基因在人群中的相对频率,它可能对免疫优势和逃逸突变的传播有重要影响。